Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02814981
Other study ID # A15-D44-VOL.27
Secondary ID
Status Recruiting
Phase N/A
First received June 17, 2016
Last updated June 23, 2016
Start date November 2015
Est. completion date October 2017

Study information

Verified date June 2016
Source University Hospital, Caen
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Observational

Clinical Trial Summary

On 04/30/2015, ANSM (the National Security Agency of Medicines and Health Products) shared an information for general practicioners, pediatricians, anesthesiologists, dermatologists, geriatricians, psychiatrists, community pharmacists and hospital about using hydroxyzine and the associated risk of QT prolongation on the electrocardiogram.

Drugs containing hydroxyzine (the best known and most used is the Atarax®) are used in France in various indications including the treatment of minor manifestations of anxiety, premedication with general anesthesia and the symptomatic treatment of urticaria.

A prolonged QT interval is a known risk factor for occurrence of torsades de pointes which can cause sudden death. We distinguish congenital and acquired long QT interval. The main cause of acquired long QT interval is a drug inhibition of the HERG potassium channel 1. Many drugs have been reported to cause sudden death by prolongation of QT interval and occurrence of torsades de pointes (macrolides, anti -arythmics, some psychotropic ...) The molecules based on hydroxyzine are known to be at risk of prolongation of QT interval in an experimental point of view but is not clearly identified in daily clinical practice. Pharmacology unit of Caen was the first to publish a case of QT prolongation under hydroxyzine . Through this publication, associated with other clinical data, hydroxyzine has been added to the list of drugs that can induce QT prolongation .

Despite these recent recommendations, it does not seem that hydroxyzine prescriptions were changed daily and therefore the risk of QT prolongation persists. We therefore propose the study of the impact of hydroxyzine on the QT interval measured on the electrocardiogram in patients hospitalized at the University Hospital of Caen.


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date October 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients hospitalized at the University Hospital of Caen with a new prescription of oral hydroxyzine by their referring doctor.

- Patient 'stable' in hospital in a health service or surgery.

- Age > 18 years old.

Exclusion Criteria:

- Unstable Patient hospitalized in an intensive care unit or intensive care.

- Patient refusing participation in the study.

- Age <18 years old.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
France Alexandre Joachim Caen Basse Normandie

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure of the corrected QT interval in ms Measure of corrected QT interval with Bazett and Frediriccia method , in DII and V5. 1 day No
Secondary Number of Incoming of torsade de pointe polymorphic ventricular tachycardia with a characteristic illusion of a twisting of the QRS complex up to 1 month No
Secondary risk of sudden death by ventricular arythmia up to 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4
Completed NCT01648205 - Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Phase 2
Recruiting NCT06087367 - Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
Recruiting NCT04675788 - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening Phase 4
Completed NCT05759962 - Phase 1 Study of LQT-1213 in Healthy Adults Phase 1
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Terminated NCT02439645 - A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Completed NCT04706104 - QT Measurement Techniques and Anesthesia Management
Recruiting NCT04336644 - Continuous Versus Intermittent cARdiac Electrical moNitorinG N/A
Completed NCT02876380 - Prospective Identification of Long QT Syndrome in Fetal Life
Completed NCT02425189 - The Canadian National Long QT Syndrome Registry
Completed NCT00399412 - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients N/A
Completed NCT02513940 - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Phase 4
Completed NCT03182777 - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies N/A
Completed NCT02441829 - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Phase 1
Completed NCT01849003 - Study of the Effect of GS-6615 in Subjects With LQT-3 Phase 1
Completed NCT00316459 - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects Phase 1
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Recruiting NCT05348564 - Comparing Direct vs Indirect Methods for Cascade Screening N/A